Elizabeth Comen
Papers
1
Total Citations
2
H-Index
1
About
Dr. Elizabeth Comen is a leading oncologist and researcher whose work focuses on the intersection of immunotherapy, cryoablation, and breast cancer treatment, particularly for aggressive subtypes like triple-negative breast cancer (TNBC). Her most-cited study, a randomized phase II trial, investigates a novel peri-operative combination of ipilimumab, nivolumab, and cryoablation versus standard care in women with residual, early-stage TNBC after neoadjuvant chemotherapy. This work addresses a critical unmet need—improving outcomes for patients with high-risk, treatment-resistant disease by leveraging immune checkpoint inhibitors alongside cryoablation to enhance antitumor immunity. While her citation count reflects the early-stage nature of this innovative research, its potential to reshape peri-operative management in TNBC is significant. Dr. Comen is also recognized for her contributions to understanding breast cancer biology and disparities, and she actively translates laboratory findings into clinical trials. Her dedication to advancing personalized, immune-based therapies positions her as a pivotal figure in the fight against resistant breast cancers, inspiring both clinicians and researchers to explore novel therapeutic synergies.
Research Focus
Key Achievements
Top Papers
- 1